Azathioprine Appears to Improve Disease Course in Early Crohn’s

Azathioprine Appears to Improve Disease Course in Early Crohn’s
Share on FacebookTweet about this on TwitterShare on LinkedIn

MONDAY, Oct. 2, 2017 (HealthDay News) — Long-term use of azathioprine (AZA) is associated with a better disease course in patients with early Crohn’s disease (CD), according to a study published online Sept. 22 in the Journal of Gastroenterology and Hepatology.

Yun Qiu, from Sun Yat-sen University in China, and colleagues evaluated the impact of AZA on disease progression in a cohort of 190 patients with early CD (disease duration ≤18 months) and no previous use of disease-modifying agents.

The researchers found that over a median follow-up of 57 months, 31 patients underwent abdominal surgeries, 48 patients were hospitalized, and 68 patients experienced clinical flares. The cumulative rate of remaining free of CD-related bowel surgery, hospitalization, and flares after five years on AZA treatment was 0.65, 0.59, and 0.39, respectively. Prior bowel resection (hazard ratio [HR], 9.23; smoking (HR, 4), and hemoglobin <110 g/L at the time of initiation of AZA (HR, 4.36) were independent predictors of CD-related operations. AZA treatment duration >36 months (HR, 0.04) was associated with reduced CD-related operations.

“Prolonged use of AZA was associated with a more favorable disease course of early CD, evident as a lower risk of CD-related surgery,” conclude the authors.

Several authors disclosed financial ties to the pharmaceutical industry.

Full Text (subscription or payment may be required)

Copyright © 2017 HealthDay. All rights reserved.

Submit a Comment

Your email address will not be published. Required fields are marked *

nineteen − 5 =